Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

Background A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …

Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the
target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …

La reacción en cadena de la polimerasa, conocida como PCR, es una técnica de biología
molecular cuyo objetivo es obtener un gran número de copias de un fragmento de ácido …

We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base
vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity …

Background We report results of immunogenicity, safety and reactogenicity of SOBERANA
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …

Objectives To evaluate heterologous scheme in children 3-18 y/o using two SARS-CoV-2 r-RBD
protein vaccines. Methods A phase I/II open-label, adaptive and multicenter trial …

… Maria Eugenia Toledo-Romani; Leslihana Verdecia Sanchez; Meybis Rodriguez Gonzalez;
Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; Belinda Sanchez …